Open-label, Combined Dose-finding (Phase I) and Efficacy-finding (Phase II) Study of RO5323441 in Combination With Bevacizumab for Patients With Recurrent Glioblastoma.
Phase of Trial: Phase I/II
Latest Information Update: 10 Jun 2016
At a glance
- Drugs Bevacizumab (Primary) ; THR 317 (Primary)
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- 29 Apr 2013 Planned end date changed from 1 Oct 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.
- 05 Dec 2012 Planned End Date changed from 1 Oct 2012 to 1 Oct 2013 as reported by ClinicalTrials.gov.
- 06 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.